⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for stage iii multiple myeloma

Every month we try and update this database with for stage iii multiple myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Bevacizumab in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT00482495
Multiple Myelom...
bevacizumab
gene expression...
protein express...
laboratory biom...
18 Years - Mayo Clinic
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple MyelomaNCT00006890
Multiple Myelom...
prednisone
thalidomide
16 Years - 120 YearsCanadian Cancer Trials Group
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative DiseaseNCT00176475
Leukemia
Lymphoma
Multiple Myelom...
rituximab
therapeutic all...
18 Years - Rutgers, The State University of New Jersey
Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple MyelomaNCT00024466
Multiple Myelom...
GVAX
Autologous tran...
18 Years - 70 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple MyelomaNCT00482846
Mucositis
Multiple Myelom...
Palifermin
melphalan
questionnaire a...
autologous peri...
quality-of-life...
18 Years - Barbara Ann Karmanos Cancer Institute
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple MyelomaNCT00005987
Multiple Myelom...
carmustine
cyclophosphamid...
dexamethasone
etoposide
filgrastim
mitoxantrone hy...
recombinant int...
sargramostim
bone marrow abl...
peripheral bloo...
radiation thera...
- 70 YearsMasonic Cancer Center, University of Minnesota
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple MyelomaNCT00243035
Refractory Mult...
Stage II Multip...
Stage III Multi...
bortezomib
tipifarnib
laboratory biom...
18 Years - National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Multiple MyelomaNCT00003149
Multiple Myelom...
recombinant int...
18 Years - National Cancer Institute (NCI)
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT00316940
Multiple Myelom...
bortezomib
samarium Sm 153...
18 Years - National Cancer Institute (NCI)
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple MyelomaNCT00504101
Multiple Myelom...
Arsenic trioxid...
Bortezomib
Melphalan
Autologous hema...
18 Years - 70 YearsUniversity of Miami
Bortezomib in Treating Patients With Newly Diagnosed Multiple MyelomaNCT00075881
Stage I Multipl...
Stage II Multip...
Stage III Multi...
bortezomib
laboratory biom...
18 Years - National Cancer Institute (NCI)
S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple MyelomaNCT00064038
Multiple Myelom...
Plasma Cell Neo...
dexamethasone
lenalidomide
placebo
18 Years - SWOG Cancer Research Network
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaNCT00729118
Multiple Myelom...
Plasma Cell Neo...
lenalidomide
vorinostat
18 Years - Ohio State University Comprehensive Cancer Center
Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple MyelomaNCT00003195
Multiple Myelom...
recombinant int...
busulfan
allogeneic bone...
peripheral bloo...
radiation thera...
18 Years - 65 YearsFred Hutchinson Cancer Center
Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or LenalidomideNCT00899080
Multiple Myelom...
gene expression...
reverse transcr...
immunoenzyme te...
laboratory biom...
platelet aggreg...
- 120 YearsEastern Cooperative Oncology Group
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple MyelomaNCT00040937
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
dexamethasone
melphalan
prednisone
thalidomide
peripheral bloo...
18 Years - 65 YearsSWOG Cancer Research Network
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic MalignancyNCT00891137
Leukemia
Lymphoma
Multiple Myelom...
Plasma Cell Neo...
Myelodysplastic...
human myeloid p...
12 Years - 65 YearsCellerant Therapeutics
CI-994 in Treating Patients With Advanced MyelomaNCT00005624
Multiple Myelom...
CI-994
18 Years - H. Lee Moffitt Cancer Center and Research Institute
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersNCT00003163
Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI)
Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple MyelomaNCT00012350
Multiple Myelom...
FTI
18 Years - H. Lee Moffitt Cancer Center and Research Institute
Activated White Blood Cells With ASCT for Newly Diagnosed Multiple MyelomaNCT00566098
Multiple Myelom...
MILs
Melphalan
PCV13
18 Years - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionNCT00118170
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI)
Bortezomib in Treating Patients With Newly Diagnosed Multiple MyelomaNCT00075881
Stage I Multipl...
Stage II Multip...
Stage III Multi...
bortezomib
laboratory biom...
18 Years - National Cancer Institute (NCI)
Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple MyelomaNCT00004165
Multiple Myelom...
filgrastim
melphalan
peripheral bloo...
- Northwestern University
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple MyelomaNCT00028886
Multiple Myelom...
filgrastim
recombinant int...
cyclophosphamid...
dexamethasone
doxorubicin hyd...
melphalan
thalidomide
vincristine sul...
bone marrow abl...
peripheral bloo...
18 Years - 65 YearsNational Cancer Institute (NCI)
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT00478075
Multiple Myelom...
bortezomib
immunologic tec...
samarium Sm 153...
18 Years - Mayo Clinic
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT00316940
Multiple Myelom...
bortezomib
samarium Sm 153...
18 Years - National Cancer Institute (NCI)
Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple MyelomaNCT00400686
Anemia
Multiple Myelom...
Plasma Cell Neo...
epoetin alfa
18 Years - The Cleveland Clinic
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaNCT00742404
Multiple Myelom...
bortezomib
dexamethasone
pegylated lipos...
protein analysi...
immunologic tec...
18 Years - National Cancer Institute (NCI)
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple MyelomaNCT00006244
Refractory Mult...
Stage I Multipl...
Stage II Multip...
Stage III Multi...
melphalan
recombinant int...
aldesleukin
in vitro-treate...
18 Years - 69 YearsFred Hutchinson Cancer Center
Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple MyelomaNCT00008242
Multiple Myelom...
dexamethasone
doxorubicin hyd...
thalidomide
18 Years - Memorial Sloan Kettering Cancer Center
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to TreatmentNCT00389701
Multiple Myelom...
bortezomib
dexamethasone
18 Years - National Cancer Institute (NCI)
Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple MyelomaNCT00003195
Multiple Myelom...
recombinant int...
busulfan
allogeneic bone...
peripheral bloo...
radiation thera...
18 Years - 65 YearsFred Hutchinson Cancer Center
Beta Alethine in Treating Patients With MyelomaNCT00006466
Multiple Myelom...
Precancerous Co...
beta alethine
18 Years - National Cancer Institute (NCI)
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic AmyloidosisNCT00007995
Multiple Myelom...
filgrastim
recombinant int...
sargramostim
busulfan
cyclophosphamid...
melphalan
autologous bone...
bone marrow abl...
peripheral bloo...
18 Years - National Cancer Institute (NCI)
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT00316940
Multiple Myelom...
bortezomib
samarium Sm 153...
18 Years - National Cancer Institute (NCI)
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple MyelomaNCT01074060
Refractory Mult...
Stage I Multipl...
Stage II Multip...
Stage III Multi...
plerixafor
filgrastim
cyclophosphamid...
autologous hema...
laboratory biom...
18 Years - 70 YearsCity of Hope Medical Center
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple MyelomaNCT00005834
Multiple Myelom...
filgrastim
cisplatin
cyclophosphamid...
dexamethasone
etoposide
thalidomide
18 Years - SWOG Cancer Research Network
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT00568880
Multiple Myelom...
bortezomib
hydroxychloroqu...
18 Years - 120 YearsAbramson Cancer Center at Penn Medicine
Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple MyelomaNCT00012350
Multiple Myelom...
FTI
18 Years - H. Lee Moffitt Cancer Center and Research Institute
S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple MyelomaNCT00064038
Multiple Myelom...
Plasma Cell Neo...
dexamethasone
lenalidomide
placebo
18 Years - SWOG Cancer Research Network
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic CancersNCT00003572
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
peripheral bloo...
mycophenolate m...
tacrolimus
allogeneic bone...
radiation thera...
18 Years - 70 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple MyelomaNCT00504101
Multiple Myelom...
Arsenic trioxid...
Bortezomib
Melphalan
Autologous hema...
18 Years - 70 YearsUniversity of Miami
Fluphenazine in Treating Patients With Refractory Advanced Multiple MyelomaNCT00335647
Multiple Myelom...
fluphenazine hy...
18 Years - National Cancer Institute (NCI)
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple MyelomaNCT00334932
Multiple Myelom...
bortezomib
melphalan
pegylated lipos...
18 Years - National Cancer Institute (NCI)
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple MyelomaNCT00398515
Refractory Mult...
Stage II Multip...
Stage III Multi...
lenalidomide
temsirolimus
pharmacological...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid CancerNCT00248430
Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
aldesleukin
therapeutic all...
melphalan
bone marrow abl...
peripheral bloo...
18 Years - 69 YearsFred Hutchinson Cancer Center
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell TransplantNCT00998049
Multiple Myelom...
Refractory Mult...
Stage I Multipl...
Stage II Multip...
Stage III Multi...
plerixafor
filgrastim
18 Years - Mayo Clinic
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionNCT00118170
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI)
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow TransplantationNCT00005641
Chronic Myelopr...
Graft Versus Ho...
Leukemia
Multiple Myelom...
Myelodysplastic...
anti-thymocyte ...
busulfan
cyclophosphamid...
cyclosporine
leucovorin calc...
methotrexate
methylprednisol...
allogeneic bone...
in vitro-treate...
radiation thera...
15 Years - 60 YearsH. Lee Moffitt Cancer Center and Research Institute
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple MyelomaNCT00743288
Multiple Myelom...
Melphalan
Panobinostat
18 Years - Oncotherapeutics
Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple MyelomaNCT00008229
Multiple Myelom...
filgrastim
melphalan
peripheral bloo...
holmium Ho 166 ...
18 Years - 70 YearsFred Hutchinson Cancer Center
Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple MyelomaNCT00014339
Multiple Myelom...
Wobe-Mugos E
melphalan
prednisone
quality-of-life...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeNCT00002989
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
busulfan
cyclophosphamid...
idarubicin
melphalan
radiation thera...
16 Years - 60 YearsNational Cancer Institute (NCI)
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple MyelomaNCT00004088
Multiple Myelom...
filgrastim
recombinant int...
busulfan
cyclophosphamid...
melphalan
pamidronate dis...
thalidomide
peripheral bloo...
- 65 YearsCity of Hope Medical Center
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple MyelomaNCT00112879
Stage I Multipl...
Stage II Multip...
Stage III Multi...
Refractory Plas...
arsenic trioxid...
ascorbic acid
dexamethasone
thalidomide
anti-cytokine t...
antiangiogenesi...
biological ther...
chemotherapy
drug resistance...
growth factor a...
non-specific im...
18 Years - National Cancer Institute (NCI)
S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple MyelomaNCT00064038
Multiple Myelom...
Plasma Cell Neo...
dexamethasone
lenalidomide
placebo
18 Years - SWOG Cancer Research Network
Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT00445484
Multiple Myelom...
pneumococcal po...
lenalidomide
18 Years - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple MyelomaNCT00002556
Stage I Multipl...
Stage II Multip...
Stage III Multi...
vincristine sul...
carmustine
melphalan
cyclophosphamid...
prednisone
recombinant int...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple MyelomaNCT00045136
Multiple Myelom...
melphalan
peripheral bloo...
holmium Ho 166 ...
18 Years - 70 YearsNational Cancer Institute (NCI)
Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple MyelomaNCT00499577
Multiple Myelom...
CMV pp65 peptid...
hTERT I540/R572...
pneumococcal po...
survivin Sur1M2...
18 Years - 80 YearsNational Cancer Institute (NCI)
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaNCT00477750
Multiple Myelom...
lenalidomide
melphalan
prednisone
18 Years - Mayo Clinic
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell TransplantNCT01534143
Refractory Mult...
Stage I Multipl...
Stage II Multip...
Stage III Multi...
pharmacological...
tacrolimus
sirolimus
anti-thymocyte ...
fludarabine pho...
busulfan
bortezomib
allogeneic hema...
laboratory biom...
18 Years - 70 YearsBarbara Ann Karmanos Cancer Institute
Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaNCT00941720
Multiple Myelom...
busulfan
cyclophosphamid...
autologous hema...
18 Years - Case Comprehensive Cancer Center
Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma PatientsNCT01653106
Refractory Mult...
Stage I Multipl...
Stage II Multip...
Stage III Multi...
cryotherapy
questionnaire a...
pharmacological...
18 Years - Ohio State University Comprehensive Cancer Center
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerNCT00296023
Chronic Myelopr...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
anti-thymocyte ...
filgrastim
therapeutic all...
busulfan
fludarabine pho...
methotrexate
tacrolimus
nonmyeloablativ...
peripheral bloo...
18 Years - 75 YearsUniversity of California, San Francisco
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With DexamethasoneNCT00522392
Stage I Multipl...
Stage II Multip...
Stage III Multi...
bortezomib
lenalidomide
dexamethasone
18 Years - National Cancer Institute (NCI)
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell TransplantNCT00998049
Multiple Myelom...
Refractory Mult...
Stage I Multipl...
Stage II Multip...
Stage III Multi...
plerixafor
filgrastim
18 Years - Mayo Clinic
PS-341 in Treating Patients With Advanced CancerNCT00006362
Leukemia
Lymphoma
Multiple Myelom...
Precancerous Co...
Unspecified Adu...
bortezomib
18 Years - Mayo Clinic
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By ChemotherapyNCT00003341
Anemia
Leukemia
Lymphoma
Multiple Myelom...
epoetin alfa
quality-of-life...
18 Years - Memorial Sloan Kettering Cancer Center
Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaNCT00941720
Multiple Myelom...
busulfan
cyclophosphamid...
autologous hema...
18 Years - Case Comprehensive Cancer Center
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaNCT01055301
Multiple Myelom...
Plasma Cell Mye...
bortezomib
cisplatin
cyclophosphamid...
dexamethasone
doxorubicin hyd...
etoposide
lenalidomide
melphalan
thalidomide
gene expression...
microarray anal...
laboratory biom...
autologous-auto...
18 Years - 65 YearsSWOG Cancer Research Network
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone PainNCT00482378
Multiple Myelom...
Pain
Pamidronate
Zoledronic acid
Sm 153 lexidron...
18 Years - 120 YearsMayo Clinic
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple MyelomaNCT01057225
Multiple Myelom...
Stage I Multipl...
Stage II Multip...
Stage III Multi...
carfilzomib
cyclophosphamid...
thalidomide
dexamethasone
18 Years - Mayo Clinic
Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney FailureNCT00416897
Multiple Myelom...
Renal Failure
chemotherapy
dexamethasone
plasmapheresis
18 Years - National Cancer Institute (NCI)
O6-benzylguanine And Carmustine in Treating Patients With Multiple MyelomaNCT00004072
Multiple Myelom...
O6-benzylguanin...
carmustine
- Case Comprehensive Cancer Center
Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell TransplantNCT00602706
Multiple Myelom...
sargramostim
melphalan
autologous hema...
peripheral bloo...
samarium Sm 153...
18 Years - Mayo Clinic
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaNCT00477750
Multiple Myelom...
lenalidomide
melphalan
prednisone
18 Years - Mayo Clinic
Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple MyelomaNCT00008229
Multiple Myelom...
filgrastim
melphalan
peripheral bloo...
holmium Ho 166 ...
18 Years - 70 YearsFred Hutchinson Cancer Center
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)NCT00075829
Multiple Myelom...
One Autologous ...
Non-Myeloablati...
Second Autologo...
Thalidomide
Dexamethasone
Observation
- 70 YearsNational Heart, Lung, and Blood Institute (NHLBI)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: